The first and third quartiles (Q) of the CHD odds ratios (OR) per standard deviation (SD) in LDL-C for HMGCR, NPC1L1, PCSK9 (or HDL-C in the case of CETP) indicated modest variability in the point estimate: (Q1 1.61, Q3 1.78) for HMGCR, (Q1 1.42, Q3 1.77) for PCSK9, (Q1 1.19, Q3 1.68) for NPC1L1, and (Q1 0.87, Q3 0.91) for CETP. Between 95 and 99% of the estimates across all four genes were in the expected direction as inferred from the findings of drugs used in clinical trials to target the corresponding proteins19–25. Here, HMGCR is linked to coronary artery disorder.